Gout News and Research

Latest Gout News and Research

$New data from Savient's KRYSTEXXA Phase III trial on refractory chronic gout$

New data from Savient's KRYSTEXXA Phase III trial on refractory chronic gout

Savient Pharmaceuticals, Inc. announced that data providing further clarity and context surrounding the risk for and management of infusion reactions that may occur with KRYSTEXXA (pegloticase) in the treatment of refractory chronic gout (RCG) patients will be presented at the American College of Rheumatology (ACR) Annual Scientific Meeting in Chicago.

7 Nov 2011

CT scans appear to help in diagnosis of gout

According to research presented at the Nov 2011, American College of Rheumatology Annual Scientific Meeting in Chicago, a type of computed tomography scanning (commonly called CT scans) appears to help in the diagnosis of gout by detecting the urate crystals that are often a symptom of the disease.

7 Nov 2011

NEJM publishes 'The 2010 Dietary Guidelines -- The Best Recipe for Health?'

USDA's interest protects that of Industry -- not the American public, conclude leading researchers Water C. Willett, MD, PhD, and David S. Ludwig, MD, PhD in their article, "The 2010 Dietary Guidelines -- The Best Recipe for Health?" published in the prestigious peer-reviewed The New England Journal of Medicine.

4 Nov 2011

Savient third quarter net loss decreases to $27.4 million

Savient Pharmaceuticals, Inc. reported financial results for the three and nine months ended September 30, 2011, which reflect the Company's continuing investment in the U.S. launch of KRYSTEXXA (pegloticase). Savient ended the quarter with $202.7 million in cash and short-term investments, a decrease of $37.6 million for the quarter.

3 Nov 2011

CMS issues J-code for Savient's KRYSTEXXA

Savient Pharmaceuticals, Inc. announced that the Centers for Medicare and Medicaid Services has assigned a product-specific billing code, or J-code, for KRYSTEXXA (pegloticase), which is used for the treatment of chronic gout in adult patients refractory to conventional therapy.

3 Nov 2011

New potential leukemia therapy targets and kills cancer cells

A new potential leukemia therapy targets only cancer cells, while leaving healthy cells alone. Many current chemotherapy treatments affect cancer cells and healthy cells, causing significant side effects, such as fatigue, hair loss, nausea, anxiety and depression.

27 Oct 2011

Study provides details on genetics behind many metabolic diseases

In what is so far the largest investigation of its kind, researchers uncovered a wide range of new insights about common diseases and how they are affected by differences between two persons' genes. The results from this study could lead to highly targeted, individualized therapies.

27 Oct 2011

ACR celebrates World Arthritis Day with the theme 'Move to Improve'

The American College of Rheumatology joins organizations from around the world in celebrating World Arthritis Day. Held every year on October 12, this year's theme is "Move to Improve" - focusing on using physical activity to combat arthritis and rheumatic diseases - such as osteoarthritis, rheumatoid arthritis, lupus, gout and psoriatic arthritis.

12 Oct 2011

Scientists identify 16M SNPs that associate with risk of gout, serum uric acid levels

Scientists at deCODE Genetics and academic collaborators from Iceland, Norway, Denmark, the Netherlands and the USA report the discovery of low frequency variants in the human genome that associate with risk of gout, a common inflammatory arthritis, and serum uric acid levels.

10 Oct 2011

Improper footwear may lead to severe foot pain, impairment and disability in gout patients

New research shows that use of poor footwear is common among patients with gout. According to the study published in Arthritis Care & Research, a peer-reviewed journal of the American College of Rheumatology (ACR), gout patients who make poor footwear choices experienced higher foot-related pain, impairment and disability. Gout patients also reported that comfort, fit, support and cost were the most important factors for selecting footwear.

3 Oct 2011

ERWW PR forms Health Buzz Group

Euro RSCG Worldwide PR (ERWW PR) announces the formation of its Health Buzz Group, a global division created in response to growing client interest in big, splashy “wows” from small budgets in quick time frames using traditional and social media to generate momentum.

20 Sep 2011

ACR launches Simple Tasks campaign to raise awareness on rheumatic diseases

The American College of Rheumatology has launched its Simple Tasks campaign. The initiative aims to raise awareness of the severe impact of rheumatic diseases - such as rheumatoid arthritis, lupus and gout - on the U.S. population and to highlight the importance of rheumatologists in the diagnosis and treatment of these diseases.

20 Sep 2011

Ardea Biosciences reports positive outcome from lesinurad End-of-Phase 2 meetings with FDA

Ardea Biosciences, Inc. announced that it has completed formal End-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA) and successfully reached agreement on the following key aspects of its proposed lesinurad Phase 3 development plan: the overall size and design of the planned Phase 3 clinical studies, the primary endpoints, the total safety database proposed for NDA filing, manufacturing plans for both drug substance and drug product, the preclinical toxicology program and the clinical pharmacology program.

7 Sep 2011

Nature journal publishes Metabolon's genome wide association study

Metabolon, Inc., the leader in metabolomics, biomarker discovery and biochemical analysis, announced the publication of "Human Metabolic Individuality in Biomedical and Pharmaceutical Research" in the journal Nature.

3 Sep 2011

New gout drug may help severely affected: Study

A new drug for gout could help very sick gout patients who don't get better with usual treatment, according to a new study. The research was designed and funded by the pharmaceutical company Savient, which markets the drug, called Krystexxa (pegloticase).

17 Aug 2011

Pegloticase can improve clinical outcomes of patients with chronic gout

Injections of pegloticase, a modified porcine enzyme, can produce significant and sustained clinical improvements in 2 out of 5 patients with chronic gout that is resistant to conventional therapies, researchers report in the August 17, 2011, issue of JAMA.

17 Aug 2011

BioCryst second quarter total revenues decrease to $3.7 million

BioCryst Pharmaceuticals, Inc. announced financial results for the second quarter and six months ended June 30, 2011.

4 Aug 2011

Researchers identify gene linked to Lesch-Nyhan disease

In humans, inherited mutations in a gene called HPRT1 lead to very specific self-destructive behavior. Boys with Lesch-Nyhan disease experience uncontrollable urges to bite their fingers, slam their arms into doorways and otherwise harm themselves.

28 Jul 2011

New study shows high prevalence of gout in the U.S.

A new study shows the prevalence of gout in the U.S. has risen over the last twenty years and now affects 8.3 million (4%) Americans.

28 Jul 2011

Positive results from sarilumab Phase 2b trial on RA, ankylosing spondylitis

Sanofi and Regeneron Pharmaceuticals, Inc. announced results from Phase 2b trials in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) with sarilumab, a novel, high-affinity, subcutaneously administered, fully-human antibody targeting the interleukin-6 receptor.

13 Jul 2011